Persistence of EBV-specific immune response. (A) Persistence of EBV-specific immune responses of responders (blue) as compared with those of nonresponders (red) in new diagnosis stratum is evident on day 90 (A). Patients with CR on day 41 demonstrated EBV-specific immune response while maintaining negative EBV viral load through 3 months after infusion (B). Patients with PR maintained EBV-specific immune response (C). Patients with PD had declining EBV-specific immune response; both patients received further therapy after day 41 evaluation with PD (D).